The company's kits enable clinical labs to identify genetic diseases, guide cancer therapy, and detect congenital defects early in pregnancy, making personalized medicine accessible and affordable. Multiplicom's partnership with diagnostic assay provider, Multiplicom, in 2011, expanded their offerings to include assays for breast cancer and cystic fibrosis. Initially focused on direct sales in Western Europe, Multiplicom aims to develop a wide range of CE-labeled diagnostic assays that help patients and doctors understand the genetic basis of diseases and predispositions.